Species Differences in Ezetimibe Glucuronidation

Area of Science:

• Pharmacology
• Drug Metabolism
• Biochemistry

Background:

• Ezetimibe, a cholesterol-absorption inhibitor, is extensively metabolized to ezetimibe glucuronide.
• Species differences in metabolism are critical for accurate pharmacokinetic and pharmacodynamic evaluations.
• Understanding ezetimibe glucuronidation variability is essential for drug development and safety assessment.

Purpose of the Study:

• To compare species differences in ezetimibe glucuronidation rates.
• To investigate ezetimibe glucuronidation using intestinal microsomes from humans, rats, mice, monkeys, and dogs.

Main Methods:

• Intestinal microsomes from multiple species were utilized.
• Ezetimibe glucuronidation rates were assessed at various substrate concentrations (0.5–50 µM).
• Enzyme kinetic parameters were determined using the Michaelis-Menten model.

Main Results:

• Significant differences in ezetimibe glucuronidation rates were found among species.
• Monkey intestinal microsomes exhibited the highest Vmax, followed by rat, mouse, human, and dog.
• Intra-species clearance (CLint) showed an 8.17-fold variation, with mouse > dog > human > rat = monkey.

Conclusions:

• Species-specific differences in intestinal ezetimibe glucuronidation rates significantly impact drug metabolism.
• These variations must be considered when analyzing ezetimibe pharmacokinetics, pharmacodynamics, and toxicology.
• Accurate interpretation of ezetimibe studies requires accounting for inter-species metabolic differences.